CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Update

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) was the target of a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 12,100 shares, a drop of 21.4% from the October 31st total of 15,400 shares. Approximately 0.2% of the company’s shares are sold short. Based on an average trading volume of 11,300 shares, the days-to-cover ratio is presently 1.1 days.

Institutional Trading of CollPlant Biotechnologies

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Villere ST Denis J & Co. LLC raised its position in shares of CollPlant Biotechnologies by 24.4% in the 3rd quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock worth $2,407,000 after acquiring an additional 95,000 shares in the last quarter. Pinnacle Associates Ltd. boosted its position in CollPlant Biotechnologies by 6.4% during the second quarter. Pinnacle Associates Ltd. now owns 564,360 shares of the company’s stock valued at $2,805,000 after purchasing an additional 33,905 shares in the last quarter. Finally, Benjamin Edwards Inc. purchased a new position in CollPlant Biotechnologies in the third quarter valued at about $112,000. Institutional investors own 21.69% of the company’s stock.

CollPlant Biotechnologies Stock Up 5.4 %

Shares of NASDAQ CLGN traded up $0.23 during midday trading on Friday, reaching $4.48. 13,919 shares of the company’s stock traded hands, compared to its average volume of 10,285. The company has a market cap of $51.30 million, a price-to-earnings ratio of -2.91 and a beta of 0.44. CollPlant Biotechnologies has a one year low of $3.31 and a one year high of $6.99. The stock’s 50 day simple moving average is $4.29 and its 200-day simple moving average is $4.84.

Wall Street Analyst Weigh In

Several research firms have commented on CLGN. EF Hutton Acquisition Co. I upgraded CollPlant Biotechnologies to a “strong-buy” rating in a report on Monday, August 5th. D. Boral Capital reissued a “buy” rating and set a $14.00 price target on shares of CollPlant Biotechnologies in a research report on Wednesday. Finally, HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of CollPlant Biotechnologies in a report on Friday.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.